静脈内フラッシュシリンジの世界市場-2025～2033年

静脈内フラッシュシリンジの世界市場は2024年に4億9,000万米ドルに達し、2033年には8億米ドルに達すると予測され、予測期間2025年にはCAGR 5.7%で成長する見込みです。

静脈内フラッシュシリンジは、主に静脈内（IV）ラインを洗浄し、透過性（開通）を保ち、詰まりを防ぐために使用される医療機器です。通常、体液に適合する滅菌生理食塩水（通常0.9%塩化ナトリウム）で構成されます。このプロセスは、多くの医療現場で、特に点滴治療で薬剤を投与される患者にとって非常に重要です。薬剤を投与した後、生理食塩水で洗浄することで、点滴ラインに残った薬剤を患者の血流に押し流し、薬剤を完全に投与することができます。多数の薬剤が同じラインを通して供給される場合、投与と投与の間にフラッシュを行うことで、相性の悪い薬剤間の相互作用の可能性を排除することができます。

静脈内フラッシュシリンジに対する需要の増加は、予測期間中の市場を牽引する要因です。慢性疾患の有病率の増加は、静脈内処置や治療の数を増やし、静脈内フラッシュシリンジの需要を増加させます。例えば、国際糖尿病連合（IDF）によると、2045年までに成人の8人に1人、約7億8,300万人が糖尿病を患うと予測されており、これは46%の増加です。糖尿病患者の90％以上は2型糖尿病で、社会経済的、人口統計的、環境的、遺伝的要因によって引き起こされます。

市場力学：

促進要因と抑制要因

静脈内フラッシュシリンジ需要の増加

静脈内フラッシュシリンジに対する需要の増加は、世界の静脈内フラッシュシリンジ市場の成長における重要な要因になると予想されます。糖尿病、心血管疾患、がんなどの慢性疾患の有病率の上昇、技術の進歩、最近の製品の発売や承認が静脈内フラッシュシリンジの需要を増加させ、市場を牽引しています。

慢性疾患の頻度上昇は市場を大きく拡大すると予測されます。糖尿病、心血管疾患、がん、慢性閉塞性肺疾患（COPD）、関節炎、骨粗鬆症はいずれも世界中で増加傾向にあり、その結果、病院への受診回数が増え、患者の在院日数も長くなっています。ヘルスケアのデータによると、毎年数百万人の患者がこれらの疾患と診断され、点滴を含む医療処置の延長を余儀なくされています。その結果、ヘルスケア施設では、点滴ラインの完全性を維持し、適切な薬物送達を確保するために不可欠な静脈内フラッシュシリンジに対する需要が増加しています。

例えば、米国疾病予防管理センターによると、20歳以上の成人の約2,010万人が冠動脈疾患を患っており、米国では約7.2%にあたります。National Center for Biotechnology Information（2023年）によると、骨粗鬆症は世界的にも熱帯諸国でも最も一般的な代謝性骨疾患です。骨粗鬆症の有病率は、閉経後の女性で30～50％、50歳以上の男性で最大20％です。さらに、世界保健機関（WHO）の2023年版によると、がん、慢性閉塞性肺疾患、喘息、糖尿病、心血管疾患などの疾患は低・中所得国の人々に影響を及ぼし、世界のNCDによる死亡者（3,140万人）の4分の3以上（80％前後）がここで発生しています。約1,700万人が70歳までにNCDで死亡しています。慢性疾患の有病率の増加は静脈内フラッシュシリンジの需要を増加させ、市場を牽引しています。

さらに、ヘルスケアのインフラとテクノロジーの継続的な向上が市場成長の原動力となっています。病院やヘルスケア施設では、患者の安全性と投薬の正確性を優先する標準的な手順の使用が増加しています。感染の危険性を減らし、正確な投与を保証するプレフィルド生理食塩水静脈内フラッシュシリンジは、ヘルスケア提供者の間で人気を集めています。この傾向は、患者の安全性の向上と医薬品の欠陥の低減を目的とした厳しい規制の中で特に重要です。その結果、メーカー各社は製品ラインナップを刷新し、ヘルスケア従事者や患者のニーズの変化に対応するため、研究開発に投資しています。

例えば、医療技術の老舗であるBDは、2023年5月、感染予防のコンプライアンスを向上させ、医師のワークフローを合理化することを目的とした、消毒ユニット一体型のオールインワン型プレフィルドフラッシュシリンジの顧客向け販売を拡大しました。BD PosiFlush SafeScrubは、注射器の先端キャップに内蔵された活性消毒ユニットを特徴とするプレフィルド生理食塩水フラッシュシリンジで、in vitro試験によりCRBSIに関連する微生物の増殖を大幅に減少させることが実証されています。

静脈内フラッシュシリンジに関連する合併症

静脈内フラッシュシリンジに関連する合併症などの要因は、世界の静脈内フラッシュシリンジ市場を阻害すると予想されます。空気塞栓症は、1つまたは複数の気泡が動脈や静脈に入り、血流が制限されることで引き起こされます。注射器や点滴が誤って静脈に空気を注入することがあります。空気塞栓症の大部分は良性であり、ごくわずかな症状が出るか、まったく症状が出ないです。これらは通常、悪影響を及ぼすことなく自然に治ります。

空気塞栓症が脳や心臓、肺に影響を及ぼすことは極めてまれです。しかし、もしそうなれば、心臓発作、脳卒中、呼吸不全を引き起こす可能性があります。さらに、体液過多とアレルギー反応の2つは、塩化ナトリウムフラッシュのより深刻な副作用です。比較的まれであるにもかかわらず、どちらも致命的であり、フラッシュシリンジの回収を増加させる可能性があります。したがって、上記の記述から、予測期間中、市場は抑制されると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 静脈内フラッシュシリンジの需要増加
  • 抑制要因
  • 静脈内フラッシュシリンジに関連する合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 製品別

• 生理食塩水フラッシュシリンジ
• ヘパリンフラッシュシリンジ

第7章 技術別

• 手動
• 自動

第8章 素材の種類別

• プラスチック
• ガラス

第9章 エンドユーザー別

• 病院
• クリニック
• ホームケア設定

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• BD
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Medline Industries, LP
• ICU Medical, Inc.
• Terumo Corporation
• SPM Medicare
• Nipro Medical Corporation
• B. Braun SE
• Cardinal Health
• Vygon
• Teleflex Incorporated

第13章 付録

The global IV flush syringe market reached US$ 0.49 billion in 2024 and is expected to reach US$ 0.80 billion by 2033, growing at a CAGR of 5.7% during the forecast period 2025-2033.

An IV flush syringe is a medical device used primarily for flushing intravenous (IV) lines, keeping them transparent (open) and free of blockages. The flush is normally made up of a sterile saline solution, usually 0.9% sodium chloride, that is compatible with the body's fluids. This process is critical in many medical settings, especially for patients receiving drugs via IV treatment. After providing drugs, a saline flush helps push any remaining drug through the IV line into the patient's bloodstream, ensuring full medication administration. When numerous medications are supplied through the same line, flushing between doses helps eliminate potential interactions between incompatible drugs.

The increasing demand for IV flush syringes is the driving factor that drives the market over the forecast period. The rising prevalence of chronic diseases increases the number of intravenous procedures and treatments which increases the demand for the IV flush syringe. For instance, according to the International Diabetes Federation, By 2045, IDF projections show that 1 in 8 adults, approximately 783 million, will be living with diabetes, an increase of 46%. Over 90% of people with diabetes have type 2 diabetes, which is driven by socio-economic, demographic, environmental, and genetic factors.

Market Dynamics: Drivers & Restraints

Increasing demand for IV flush syringes

Increasing demand for IV flush syringes is expected to be a significant factor in the growth of the global IV flush syringe market. The rising prevalence of chronic diseases, such as diabetes, cardiovascular conditions, and cancer, technological advancements, and recent product launches and approvals increase the demand for the IV flush syringe and drive the market.

The rising frequency of chronic diseases is predicted to significantly expand the market. Diabetes, cardiovascular diseases, cancer, chronic obstructive pulmonary disease (COPD), and arthritis, osteoporosis are all on the rise across the globe, resulting in more hospital visits and longer patient stays. According to healthcare data, millions of patients are diagnosed with these disorders each year, necessitating extending medical care, which frequently includes intravenous medicines. As a result, healthcare facilities are experiencing an increase in demand for IV flush syringes, which are critical for preserving the integrity of IV lines and ensuring proper medication delivery.

For instance, according to the Centers for Disease Control and Prevention, around 20.1 Million adults aged 20 and older have coronary artery disease, about 7.2% in the United States. According to the National Center for Biotechnology Information, 2023, Osteoporosis is the most common metabolic bone disorder globally and in tropical countries. The prevalence of osteoporosis is 30 to 50% among postmenopausal women and up to 20% in men above 50 years. Furthermore, according to the World Health Organization, 2023, diseases like cancers, chronic obstructive pulmonary diseases, asthma, diabetes, and cardiovascular diseases affect people in low- and middle-income countries, where more than three-quarters of global NCD deaths (31.4 million) occur around up to 80%. Approximately 17 million people die from an NCD before age 70. The increasing prevalence of chronic diseases increases the demand for IV flush syringes and drives the market.

Furthermore, continual improvements in healthcare infrastructure and technology are driving market growth. Hospitals and healthcare facilities are increasingly using standard procedures that prioritize patient safety and medication accuracy. Prefilled saline IV flush syringes, which reduce the danger of infection and ensure accurate dosing, are gaining popularity among healthcare providers. This tendency is especially important in the context of strict restrictions aimed at improving patient safety and lowering pharmaceutical faults. As a result, manufacturers are investing in R&D to reinvent their product offerings and meet the changing needs of healthcare practitioners and patients alike.

For instance, in May 2023, BD, an established medical technology firm, expanded customer availability of an all-in-one prefilled flush syringe with an integrated disinfection unit, which is meant to improve infection prevention compliance and streamline physician workflow. BD PosiFlush SafeScrub is a prefilled saline flush syringe that features an active disinfection unit built right into the tip cap of the syringe that is demonstrated via in vitro testing to significantly reduce microbial growth associated with CRBSIs.

Complications associated with IV flush syringes

Factors such as complications associated with IV flush syringes are expected to hamper the global IV flush syringe market. An air embolism develops when one or more air bubbles enter an artery or vein and restrict blood flow. A syringe or IV can inadvertently inject air into a vein. The majority of air embolisms are benign, producing very subtle symptoms or none at all. These typically go away on their own without having any negative effects.

However, air embolisms are extremely rare and rarely affect the brain, heart, or lungs. If they do, a heart attack, stroke, or respiratory failure could result. Moreover, fluid overload and an allergic reaction are two more severe side effects of a sodium chloride flush. Despite being relatively uncommon, both can be fatal and increase recalls of flush syringes. Thus, from the above statements, the market is expected to be hampered in the forecast period.

Segment Analysis

The global IV flush syringe market is segmented based on offerings, application, type, end-user, and region.

Saline flush syringes segment is expected to dominate the global IV flush syringe market share

One of the primary drivers of this trend is an increasing awareness of the need to preserve IV-line patency in clinical settings. Saline flush syringes, particularly prefilled ones, offer healthcare providers a convenient and efficient way to drain intravenous lines, ensuring that medications are given effectively and without interruption. This is critical in managing patients with chronic disorders, who frequently require continual intravenous therapy. As hospitals and clinics aim to improve patient safety and streamline processes, the use of saline flush syringes is projected to increase significantly.

The segment benefits because the hazards of microbial contamination that arise when doses are drawn up at the ward level are eliminated by the use of prefilled saline syringes. Additionally, the chance of incorrect selection is decreased by the completely labeled nature of prefilled syringes. The time saved by nurses is another important issue. Ad hoc preparation of intravenous dosages incurs costs (including disposables and nurse time) that are frequently disregarded but can pile up in a busy ward. According to one study, using prefilled syringes reduced nursing time by 42% compared to using traditional injection systems.

Furthermore, developments in medical technology and product design enable saline flush syringes to maintain their market dominance. Manufacturers are concentrating on creating novel prefilled saline syringes that shorten the preparation time and limit the danger of contamination. These solutions not only improve healthcare staff workflow efficiency but also increase patient safety by lowering the risk of needlestick injuries and infections. For instance, in September 2023, AMSINO launched the Prefilled Normal Saline Flush Syringe. This product is intended to improve the safety and efficiency of intravenous therapy by offering a prefilled saline solution that reduces the risk of contamination and makes the flushing procedure easier for healthcare practitioners. The syringes are DEHP-free, PVC-free, and latex-free, fulfilling contemporary requirements for patient safety and comfort.

Geographical Analysis

North America is expected to hold a significant position in the global IV flush syringe market share

The dominance of the North American market in the global IV flush syringe market is driven by several key factors such as the high concentration of hospitals, clinics, and specialized medical facilities, and the increasing prevalence of chronic diseases.

The rising incidence of chronic diseases in North America is driving up demand for IV flush syringes. Diabetes, cardiovascular disease, and cancer are becoming more prevalent, resulting in increasing hospitalization rates and a growing demand for effective medication administration systems. According to American Hospital Association data, hospital admissions in the United States have been constantly increasing, with millions of patients requiring intravenous therapies that use flush syringes.

For instance, according to the National Institute of Health, in 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths. Prostate cancer incidence climbed by 3% every year from 2014 to 2019, after two decades of reduction, resulting in an additional 99,000 new cases. The annual cancer incidence rate is 440.5 per 100,000 men and women (based on cases from 2017 to 2021). The cancer death rate (cancer mortality) is 146.0 per 100,000 men and women annually. In 2024, a projected 14,910 children and adolescents between the ages of 0 and 19 will be diagnosed with cancer, with 1,590 deaths from the condition. The rising incidence of chronic diseases increases the number of intravenous treatments which increases the demand for IV flush syringes and drives the market.

Asia Pacific is growing at the fastest pace in the global IV flush syringe market

The Asia Pacific region is experiencing the highest growth in the around-the-globe IV flush syringe market, owing to many important factors. The rising frequency of chronic diseases in the region is a major cause of its rapid growth. With a growing population suffering health issues such as diabetes, cardiovascular disease, and respiratory ailments, the demand for effective medical treatments, such as IV flush syringes, has increased dramatically. This trend is accelerated by the increasing number of hospital admissions and surgical procedures that require the use of IV flush syringes to maintain clear intravenous lines and ensure efficient medication delivery.

For instance, according to the National Institute of Health, the expected number of cancer cases in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Males and females were most likely to develop lung and breast cancer, respectively. The rising incidence of chronic diseases increases the demand for IV flush syringes and drives the market due to an increase in the intravenous market.

Competitive Landscape

The major global players in the global IV flush syringe market include BD, Medline Industries, LP, ICU Medical, Inc., Terumo Corporation, SPM Medicare, Nipro Medical Corporation, B. Braun SE, Cardinal Health, Vygon, Teleflex Incorporated among others.

Emerging Players

Aquabiliti, Polymedicure, and Medefil, Inc among others

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global IV flush syringe market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Technology
• 3.3. Snippet by Material Type
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Demand for IV Flush Syringes
  • 4.1.3. Restraints
  • 4.1.4. Complications associated with IV Flush Syringe
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Saline Flush Syringes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Heparin Flush Syringes

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. Manual*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Automated

8. By Material Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 8.1.2. Market Attractiveness Index, By Material Type
• 8.2. Plastic*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Glass

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Homecare Settings

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.2.8. The U.S.
  • 10.2.9. Canada
  • 10.2.10. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.3.8. Germany
  • 10.3.9. UK
  • 10.3.10. France
  • 10.3.11. Italy
  • 10.3.12. Spain
  • 10.3.13. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.4.8. Brazil
  • 10.4.9. Argentina
  • 10.4.10. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.5.8. China
  • 10.5.9. India
  • 10.5.10. Japan
  • 10.5.11. South Korea
  • 10.5.12. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. BD*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Medline Industries, LP
• 12.3. ICU Medical, Inc.
• 12.4. Terumo Corporation
• 12.5. SPM Medicare
• 12.6. Nipro Medical Corporation
• 12.7. B. Braun SE
• 12.8. Cardinal Health
• 12.9. Vygon
• 12.10. Teleflex Incorporated

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us